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In most cases, sacral neuromodulation is used as a treatment for urge incontinence and symptoms of
urgency and frequency. It is most used in those who are refractory to traditional management. It is much
less common to be used for bladder atony. In this report, we present a case of a 24-year-old woman with
a history of urinary retention and bladder atony who failed medical management and subsequently had
an InterStim sacral neuromodulator implanted. After implantation, she was able to discontinue inter-
mittent catheterization and had a decrease in her postvoid residual from 848 to 72 mL.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Sacral neuromodulation (ie, InterStim) has been shown to be an
effective treatment for a variety of bladder control issues. It was ﬁrst
introduced by Tanagho and Schmidt in 1981 and approved by the
Food and Drug Administration for the treatment of urge inconti-
nence in 1991. In 1999, it was approved for the treatment of urinary
retention and urinary frequency.1 This technique involves the sur-
gical implantation of a device in the abdomen or buttock region,
which is then attached to an electrode to stimulate sacral nerves.2
InterStim uses electrical impulses to modulate afferent sacral sig-
nals through inhibition. These impulses modulate the nerves and
muscles used to control the bladder.3 This reversible treatment
option has been shown to be successful in existing research.
Speciﬁcally, current research has shown that sacral neuro-
modulation can be used to successfully treat urinary urge inconti-
nence, urgency frequency, urinary retention, and even fecal
incontinence.2 Recent research focuses primarily on sacral neuro-
modulation in conjunction with non-neurogenic urinary tract
dysfunction.1 However, a study by Wallace et al3 demonstrated theInc. Open access under CC BY-NC-Neffectiveness of sacral neuromodulation on patients with underly-
ing neurologic disease, ranging from multiple sclerosis and Par-
kinson disease to spina biﬁda and spinal cord disease. This research
seems to indicate that InterStim therapy can be successful in cases
of nonobstructive bladder control issues in patients with neuro-
genic or non-neurogenic causes.Case presentation
EM is a 24-year-old womanwho presented with a history urinary
retention brought on by stress since early premenstrual childhood.
She reported multiple episodes in which she would become spon-
taneously unable to urinate and have painless retention. This
necessitated multiple trips to the emergency room, in which a
catheter was temporarily placed for urinary retention. She had no
pertinent past urologic history except for these episodes. She had no
known neurologic issues and no history of constipation.
After a recent episode of stress urinary retention, the patient
presented to the ofﬁce for outpatient urologic evaluation. A
maximum postvoid residual (PVR) was found to be 848 mL. A trial
of Flomax was given but discontinued because of orthostatic side
effects. At this time, the patient underwent urodynamics (UDS). She
was found to have no sensation of ﬁlling at 464 mL with no
measurable detrusor voiding pressure (Fig. 1). Findings were most
consistent with an atonic, high capacity bladder. Her surface patch
electromyography recording was normal, and she was unable to
void after UDS.D license.
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times daily. She reported no difﬁculty self-catheterizing but had
several catheter-associated urinary tract infections and was treated
appropriately with standard oral antibiotics. After 3 months of
intermittent catheterization and no signiﬁcant reduction in her PVR,Figure 1. Urodynamics Ssheunderwent amagnetic resonance imagingof the spine to ruleout
anoccult neurologic process. Imaging studies showednoevidenceof
cystic ovaries or occult neurologic processes. Shewas considered for
reduction cystoplasty surgery, but in aneffort to avoidmajor surgery,
she instead underwent a sacral neuromodulation test procedure.tudy of our Patient.
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using the Medtronic unit. With reduction in the frequency of cath-
eterization to twice daily, her residual volume was reduced to 100
mL on follow-up just 2 weeks later. She subsequently underwent
generator placement and has been able to wean off of catheteriza-
tion entirely with a most recent PVR of 72 mL.
Discussion
Typically, sacral neuromodulation has been used for the treat-
ment of urge incontinence and symptoms of urgency and fre-
quency. Its use for the treatment of urinary retention and bladder
atony is less well established. Jonas et al1 studied 177 patients with
chronic urinary retention refractory to standard therapy. These
patients were qualiﬁed for surgical implantation of InterStim
through a 3-7eday percutaneous test. Those with a 50% or greater
improvement in baseline voiding symptoms were then enrolled
into a control group (n ¼ 31) or an implantation group (n ¼ 37). Of
those patients treated with implants, 69% eliminated the need for
intermittent catheterization, and an additional 14% had a >50%
reduction of catheterization volume. A decrease in PVR was found
in 83% of the implanted group as compared with 9% of the control
group at 6 months. These ﬁndings were found to be statistically
signiﬁcant and were maintained even after a trial deactivation of
the implant. This indicates that although the implant did not treat
the underlying pathology, it did modulate the underlying
dysfunctional system and allowed for more normal voiding.
A smaller study by Denzinger et al4 examined reduction of
intermittent catheterization with sacral neuromodulation. Twenty
patients were enrolled to receive InterStim, and it was found that 18
of 20 (90%) had a decrease in their PVR and the number of cathe-
terizations per day. The results did not reach statistical signiﬁcance,
but the author hypothesized this was because of the small size of
the study.
Chaabane et al5 further examined sacral neuromodulation for
treating neurogenic bladder. Over a 10-year interval, 62 patients
were evaluated for placement of a sacral device; of these, only 37
were implanted. Of the original 62 patients, 28 were noted to have
urinary retention; however, it is not indicated how many of the 37
implants were placed in this population. The remaining population
had detrusor overactivity (n ¼ 34) or detrusor-sphincter dyssy-
nergia (n ¼ 9). In the implanted population, 75% had a 50% or
greater improvement of their UDS testing.
One possibility is that our patient had Fowler’s syndrome. This
syndrome is characterized by painless urinary retention in young
women and is thought to be because of failure of urethral sphincter
relaxation.6 Typically, patients are approximately between the ages
of 20-35 years at ﬁrst presentation and have a triggering event, suchas an operation or childbirth. This leads to infrequent voiding and
intermittent stream, which then progress to urinary retention. The
deﬁnitive test for diagnosis is electromyography sampling of the
urethral sphincter using a concentric needle electrode. Although it
is not possible to retrospectively rule out this syndrome, our patient
had characteristics that were different from patients with typical
Fowler’s syndrome. She had complete bladder atony, whereas pa-
tients with Fowler’s syndrome usually have some measurable
detrusor voiding pressure. As well, our patient had experienced
these episodes since very early childhood and only had stress as a
precipitating event. A smaller point is that she had no cysts in her
ovaries which can be seen in >50% of patients with Fowler’s syn-
drome. If the patient did have Fowler’s syndrome, she was treated
appropriately, as sacral neuromodulation is the treatment of choice
for this syndrome.
In our case, the patient clearly beneﬁted from her implant and
further supports the use for sacral neuromodulation for the man-
agement of refractory urinary retention and bladder atony, not just
urge incontinence and symptoms of urgency and frequency.Conclusion
The use of sacral neuromodulation for urinary retention is not
new, but its efﬁcacy and utility for complete bladder atony have yet
to be fully established. To our knowledge, sacral neuromodulation
has not been reliably shown to be efﬁcacious in cases of severe
bladder atony. This case reiterates that sacral neuromodulation
might be a valuable tool in this setting, and in light of our ﬁndings,
bears further investigation by the urologic community as to the
continued expansion of its indications. Clearly, in this case, it was
a valuable and spared our patient from both ongoing self-
catheterization and major surgery.References
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